Trials / Completed
CompletedNCT01709656
A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will recruit active ankylosing spondylitis patients for injection treatment of Human Mesenchymal Stem Cells (a prospective, open-label, masculine medicine controlled(NSAIDs), clinical trial), and collect their Peripheral Blood Lymphocyte (PBMCs) and sera before and after the treatment of 24 weeks to test the gene expression profiles and study related pathogenesis of AS
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MSC | human mesenchymal stem cells,1\*10\^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment. a total of 24 weeks for follow up. |
| DRUG | "celecoxib", "Celebrex®" | non-steroid anti-inflammatory drugs (NSAID):"celecoxib", "Celebrex®" 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2012-10-18
- Last updated
- 2015-02-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01709656. Inclusion in this directory is not an endorsement.